
|Videos|March 15, 2016
To What Extent Should People Have Access to Naloxone?
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, outlines his pros and cons for expanded access to naloxone.
Advertisement
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, outlines his pros and cons for expanded access to naloxone.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
3
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
4
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
5








































































































































